Vertex dominates cystic-fibrosis treatment and just launched the first strong non-opioid painkiller.
Vertex Pharmaceuticals Incorporated (VRTX) is expected to report earnings on Monday, November 2, 2026, after the close. Estimated release time 16:06 ET. Consensus EPS estimate is $4.76.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-03 | Jun 2026 qtr | $4.74 | $4.20 | -11.4% | $3.33B |
| 2026-05-05 | Mar 2026 qtr | $4.24 | $4.47 | +5.4% | $2.99B |
| 2026-02-13 | Dec 2025 qtr | $5.11 | $5.03 | -1.6% | $3.23B |
| 2025-11-04 | Sep 2025 qtr | $4.57 | $4.80 | +5.0% | $3.08B |
| 2025-08-05 | Jun 2025 qtr | $4.29 | $4.52 | +5.4% | $2.96B |
| 2025-05-06 | Mar 2025 qtr | $4.25 | $4.06 | -4.5% | $2.77B |
| 2025-02-10 | Dec 2024 qtr | $4.02 | $3.98 | -1.0% | $2.91B |
| 2024-11-05 | Sep 2024 qtr | $4.14 | $4.38 | +5.8% | $2.77B |
VRTX has beaten consensus EPS in 4 of its last 8 scored quarters.
See VRTX on the live calendar →